Comparison · NCT02002650-8a96801e
Pre-ERCP Group vs Post-ERCP Group: Post-ERCP Pancreatitis
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pre-ERCP Group vs Post-ERCP Group: Post-ERCP Pancreatitis. Trial comparisons, record NCT02002650-8a96801e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02002650-8a96801e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0362 | 0.0274 | 0.0479 | wilson | |
| Risk in group 2 | 0.0767 | 0.0635 | 0.0925 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0405 | -0.0586 | -0.0229 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.472 | 0.337 | 0.662 | log | |
| Odds ratio, group 1 over group 2 | 0.452 | 0.317 | 0.645 | log | |
| Number needed to treat, for one fewer participant with the outcome on Pre-ERCP Group than on Post-ERCP Group | 24.7 | 17.1 | 43.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pre-ERCP Group | Pre-ERCP rectal Indomethacin in all patients.~Pre-ERCP rectal Indomethacin: Rectal Indomethacin was administrated within 30min before ERCP in all patients. | 47 | 1,297 | OG000 |
| Group 2 | Post-ERCP Group | Post-ERCP rectal Indomethacin in high-risk patients.~Post-ERCP Rectal Indomethacin: Rectal Indomethacin was administrated immediately after ERCP just in high-risk patients, while average risk patients did not. | 100 | 1,303 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Post-ERCP Pancreatitis
- Description
Subjects were diagnosed with post-ERCP pancreatitis if they experienced new upper abdominal pain, serum amylase elevation at least three times the upper limit of normal 24 hours after the procedure, and hospitalization prolonged at least two nights.
- Time frame
- 30 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
- NCT number
- NCT02002650
- Phases
- NA
- Conditions
- Post-ERCP Acute Pancreatitis
- Interventions
- Pre-ERCP rectal Indomethacin, Post-operational Rectal Indomethacin
- Lead sponsor
- Air Force Military Medical University, China
- Results first posted
- 2016-05-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02002650?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02002650-8a96801e